Cargando…
Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estr...
Autor principal: | Morita, Tatsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658217/ https://www.ncbi.nlm.nih.gov/pubmed/23754886 |
Ejemplares similares
-
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
por: Nakano, Kazuhiko, et al.
Publicado: (2012) -
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997) -
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
por: Albrecht, W, et al.
Publicado: (2004) -
Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007) -
Pheochromocytoma with Markedly Abnormal Liver Function Tests and Severe Leukocytosis
por: Eun, Chai Ryoung, et al.
Publicado: (2014)